Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: A report from the DECIDE study group

Keyphrases

• Prostate Cancer Patients 100%
• Treatment Recommendations 100%
• Postoperative Treatment 100%
• Genomic Classifier 100%
• Metastatic Risk 100%
• Urologists 50%
• Postgenomics 40%
• Post-radical Prostatectomy 30%
• Metastasis Risk 30%
• Radical Prostatectomy 20%
• Treatment Decisions 20%
• Biochemical Recurrence 20%
• Epigenetic Biomarkers 20%
• High Risk 10%
• Routine Clinical Practice 10%
• Risk Stratification 10%
• Utility Study 10%
• Metastasis 10%
• Clinical Information 10%
• Prostate Cancer 10%
• Patients at Risk 10%
• Prediction Model 10%
• Oncologists 10%
• De-identified 10%
• Validation Studies 10%
• Pathology Report 10%
• Genomic Risk 10%
• Genomic Information 10%
• Heterogeneous Population 10%
• Clinical Utility 10%
• Close Observation 10%
• Practice Setting 10%
• Consistent Patterns 10%
• Treatment Costs 10%
• Urologic 10%
• Risk Prediction Model 10%
• Neoadjuvant Setting 10%
• Direct Treatment 10%
• Pre-post Design 10%
• Adverse Pathology 10%
• Secondary Therapy 10%
• Classifier Validation 10%
• Observation post 10%

Medicine and Dentistry

• Prostatectomy 100%
• Prostate Cancer 100%
• Urologist 100%
• Postoperative Care 100%
• Metastatic Carcinoma 80%
• Biological Marker 40%
• Biochemical Recurrence 40%
• Health Care Cost 20%
• Clinician 20%
• Risk Stratification 20%
• Decision Making 20%
• Oncologist 20%
• Adjuvant 20%